The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma-Reference-Cited by-同舟云学术

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

Published:2005-03 Issue:3 Volume:60 Page:302-308
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:

Author:

Bousquet J.,Cabrera P.,Berkman N.,Buhl R.,Holgate S.,Wenzel S.,Fox H.,Hedgecock S.,Blogg M.,Cioppa G. Della

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1398-9995.2004.00770.x/fullpdf

Reference25 articles.

1. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma;Weber;Am J Med,2002

2. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma;Hartert;Ann Allergy Asthma Immunol,2002

3. Multicenter Airway Research Collaboration Investigators. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma;Pollack;Arch Pediatr Adolesc Med,2002

4. Asthma deaths; persistent and preventable mortality;Sidebotham;Histopathology,2003

5. Risk factors for asthma deaths: a population-based, case-control study;Jalaludin;Aust N Z J Public Health,1999

Cited by 348 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study;American Journal of Respiratory and Critical Care Medicine;2024-08-01

2. Potential of the domestic biosimile omalizumab in achievement of control in patients with severe asthma: short communication;Russian Journal of Allergy;2024-04-15

3. The Incredible Adventure of Omalizumab;International Journal of Molecular Sciences;2024-03-06

4. A Randomized, Single‐Dose, Parallel‐Controlled Phase I Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers;Clinical Pharmacology in Drug Development;2023-12-06

5. A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate‐to‐severe asthma;Clinical and Translational Allergy;2023-11